Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity

Science
J W BurnsH B Greenberg

Abstract

Rotaviruses are the leading cause of severe gastroenteritis and dehydrating diarrhea in young children and animals worldwide. A murine model and "backpack tumor" transplantation were used to determine the protective effect of antibodies against VP4(an outer capsid viral protein) and VP6(a major inner capsid viral protein). Only two non-neutralizing immunoglobulin A (IgA) antibodies to VP6 were capable of preventing primary and resolving chronic murine rotavirus infections. These antibodies were not active, however, when presented directly to the luminal side of the intestinal tract. These findings support the hypothesis that in vivo intracellular viral inactivation by secretory IgA during transcytosis is a mechanism of host defense against rotavirus infection.

References

Aug 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·M B MazanecJ G Nedrud
Oct 1, 1992·Physiological Reviews·J P Kraehenbuhl, M R Neutra
Oct 1, 1990·Journal of Virology·R L WardJ F Sheridan
Dec 1, 1986·Virology·R D ShawH B Greenberg
Jan 1, 1989·Advances in Virus Research·S M MatsuiH B Greenberg
Jan 1, 1989·Annual Review of Microbiology·N K ChildersJ R McGhee
Dec 1, 1989·Microbiological Reviews·M K Estes, J Cohen
Mar 11, 1983·Science·R T Taggart, I M Samloff
Feb 20, 1995·Virology·J W BurnsH B Greenberg
Sep 2, 1994·Science·R I GlassJ C Smith
Sep 1, 1993·Immunology Today·M B MazanecM E Lamm
Mar 1, 1993·The Journal of Infectious Diseases·D O MatsonM K Estes

❮ Previous
Next ❯

Citations

Sep 29, 1999·Journal of Medical Virology·K JohansenL Svensson
Mar 23, 2001·Reviews in Medical Virology·H IijimaH Kiyono
Jan 1, 1997·Springer Seminars in Immunopathology·P BrandtzaegJ Rugtveit
Nov 30, 2005·Transgenic Research·Eric SolerLouis-Marie Houdebine
Nov 27, 1999·International Journal for Parasitology·D C de GraafA Bonnin
Feb 12, 1998·Journal of Reproductive Immunology·M B Parr, E L Parr
Oct 9, 1998·Veterinary Immunology and Immunopathology·L A van PinxterenD R Snodgrass
Oct 16, 1999·Veterinary Immunology and Immunopathology·L A van PinxterenD R Snodgrass
Jun 1, 1997·Vaccine·S C ChenJ E Herrmann
Sep 21, 2002·Molecular and Cellular Endocrinology·A Rincheval-ArnoldJ Djiane
Dec 14, 1999·Microbes and Infection·F LaurentM F Kagnoff
Mar 6, 1999·Current Opinion in Microbiology·A A Lindberg
Mar 29, 2001·Trends in Immunology·M van EgmondJ G van de Winkel
Feb 13, 2008·Expert Reviews in Molecular Medicine·Richard L Ward
May 19, 1998·Nature Medicine·P J Sansonetti
Oct 30, 2012·Nature Reviews. Immunology·Oliver Pabst
Sep 5, 2002·Nature Reviews. Immunology·Dennis R Burton
Aug 10, 2010·Nature Reviews. Microbiology·Richard A Strugnell, Odilia L C Wijburg
Dec 17, 1998·Tropical Medicine & International Health : TM & IH·M J CoxG F Medley
Nov 2, 2011·Proceedings of the National Academy of Sciences of the United States of America·Yu BaiXiaoping Zhu
Jan 24, 2002·The Journal of Experimental Medicine·Edward P BowmanEugene C Butcher
Apr 1, 1999·The Journal of Infectious Diseases·M A Franco, H B Greenberg
Jul 1, 1997·AIDS Research and Human Retroviruses·J M WinchellL K Silbart

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriotherapy (ASM)

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.

Bacteriotherapy

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.